 9. Females with child-bearing potential FCBP must agree to use 2 reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study including during dose interruptions, and for at least 28 days after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe. For subjects enrolled in Cohort B, pregnancy prevention and testing will continue until 3 months after last dose of daratumumab. 